These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21422924)

  • 41. [CKD-MBD (chronic kidney disease-mineral and bone disorder). CKD-MBD: chronic kidney disease-mineral and bone disorder].
    Mizobuchi M; Aoshima Y; Akizawa T
    Clin Calcium; 2010 Jul; 20(7):995-1003. PubMed ID: 20585177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experimental study of the mechanism for vascular calcification in chronic kidney disease].
    Persy V
    Verh K Acad Geneeskd Belg; 2008; 70(4):285-303. PubMed ID: 19166100
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?
    Levin A; Li YC
    Kidney Int; 2005 Nov; 68(5):1973-81. PubMed ID: 16221197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5.
    García-Canton C; Bosch E; Ramírez A; Gonzalez Y; Auyanet I; Guerra R; Perez MA; Fernández E; Toledo A; Lago M; Checa MD
    Nephrol Dial Transplant; 2011 Jul; 26(7):2250-6. PubMed ID: 20956810
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?
    Covic A; Voroneanu L; Goldsmith D
    Nephron Clin Pract; 2010; 116(3):c187-95. PubMed ID: 20606478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
    Toussaint ND; Elder GJ; Kerr PG
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of vitamin D in vascular calcification in chronic kidney disease.
    Wolisi GO; Moe SM
    Semin Dial; 2005; 18(4):307-14. PubMed ID: 16076354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress in therapy of CKD-MBD with vitamin D receptor activators].
    Shoji T
    Clin Calcium; 2012 Jul; 22(7):1073-81. PubMed ID: 22750940
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review article: Getting the balance right: assessing causes and extent of vascular calcification in chronic kidney disease.
    Ketteler M; Biggar PH
    Nephrology (Carlton); 2009 Jun; 14(4):389-94. PubMed ID: 19563380
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
    Yano S
    Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic kidney disease-mineral-bone disorder: a new paradigm.
    Moe SM; Drüeke T; Lameire N; Eknoyan G
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):3-12. PubMed ID: 17200038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder.
    Bover J; Canal C; Marco H; Fernandez-Llama P; Bosch RJ; Ballarín J
    Contrib Nephrol; 2008; 161():222-233. PubMed ID: 18451681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Kidney and bone update : the 5-year history and future of CKD-MBD. Vascular calcification in CKD patients].
    Joki N; Iwasaki M
    Clin Calcium; 2012 Jul; 22(7):993-9. PubMed ID: 22750931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Structural changes and vascular calcifications in uremia].
    Caramelo C; Goicoechea M; Albalate M; Nieto L; Melero R; Berlanga JR; López MD; González Pacheco F; Marrón B; Alvarez Arroyo MV; Castilla MA; Yagüe S; Deudero JJ; Ortiz A
    Nefrologia; 2001; 21(6):538-47. PubMed ID: 11881423
    [No Abstract]   [Full Text] [Related]  

  • 58. Vasculotropic effects of calcimimetics.
    Koleganova N; Piecha G; Ritz E
    Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):32-6. PubMed ID: 19816173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.
    Covic A; Kothawala P; Bernal M; Robbins S; Chalian A; Goldsmith D
    Nephrol Dial Transplant; 2009 May; 24(5):1506-23. PubMed ID: 19001560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extracellular matrix calcification in chronic kidney disease.
    Toussaint ND
    Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):360-8. PubMed ID: 21537176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.